The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Updates from the FORTE trial: the role of PET-CT
In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses some updates from the Phase II FORTE trial (NCT02203643), highlighting the progression-free survival (PFS) and overall survival (OS) observed, and the importance of applying PET-CT imaging in myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Honoraria and advisory board member for Janssen, Sanofi, BMS, Roche, Amgen, GSK, Pfizer
